Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 10/20 | 0.63 |
| ▸ | WNT3A | P56704 | 8/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.59 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | CES2 | O00748 | 1/20 | 0.55 |
| ▸ | CES1 | P23141 | 1/20 | 0.55 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30609612 | 1.00 | CTNNB1 (0.63) | CTNNB1WNT3ALMNANAPRTP4HTM | |
| SCHEMBL2470002 | 0.92 | CTNNB1 (0.71) | CTNNB1WNT3ALMNANAPRTP4HTM | |
| SCHEMBL5849694 | 0.89 | CTNNB1 (0.59) | CTNNB1WNT3ALMNANAPRTP4HTM | |
| SCHEMBL29884496 | 0.89 | CTNNB1 (0.59) | CTNNB1WNT3ALMNANAPRTP4HTM | |
| SCHEMBL2418294 | 0.89 | CTNNB1 (0.55) | CTNNB1WNT3ALMNANAPRTP4HTM | |
| SCHEMBL3380712 | 0.87 | HDAC1 (0.58) | CTNNB1WNT3ALMNANAPRTP4HTM | |
| SCHEMBL9196964 | 0.87 | CTNNB1 (0.68) | CTNNB1WNT3ALMNANAPRTP4HTM | |
| SCHEMBL15980176 | 0.85 | CTNNB1 (0.65) | CTNNB1WNT3ALMNANAPRTP4HTM | |
| Succinic Acid SCHEMBL27770028 | 0.83 | LMNA (0.57) | CTNNB1WNT3ALMNANAPRTP4HTM | |
| Succinic Acid SCHEMBL27770027 | 0.83 | LMNA (0.57) | CTNNB1WNT3ALMNANAPRTP4HTM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4156091-A | 11-Deoxy-11-hydroxymethyl-6-hydroxy-PGE1 compounds | THE UPJOHN COMPANY (US) | 1979-05-22 | — | — | US | claimed |
| US-11718588-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | GALAPAGOS NV (BE) | 2023-08-08 | — | — | US | disclosed |
| US-20170152443-A1 | LIQUID CRYSTAL ALIGNMENT AGENT, LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY ELEMENT | CHI MEI CORPORATION (TW) | 2017-06-01 | — | — | US | disclosed |
| US-20170152443-A1 | LIQUID CRYSTAL ALIGNMENT AGENT, LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY ELEMENT | CHI MEI CORPORATION (TW) | 2017-06-01 | — | — | US | disclosed |
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | BLANEY JEFFREY MARK | 2008-08-21 | — | — | US | disclosed |
| WO-2008098859-A1 | HCV POLYMERASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-21 | — | — | WO | disclosed |
| EP-0496555-B1 | Corrosion-inhibiting coating compositions | CIBA GEIGY AG (CH) | 1997-11-19 | — | — | EP | disclosed |
| US-5277709-A | Film forming binder and corrosion inhibitor | CIBA-GEIGY CORPORATION (US) | 1994-01-11 | — | — | US | disclosed |
| EP-0496555-A2 | Corrosion-inhibiting coating compositions | CIBA-GEIGY AG (CH) | 1992-07-29 | — | — | EP | disclosed |
| US-4725580-A | ARTERIAL TENSION | SANOFI (FR) | 1988-02-16 | — | — | US | disclosed |
| US-4342690-A | HHYPOTENSIVE AGE TS | AMERICAN CYANAMID COMPANY (US) | 1982-08-03 | — | — | US | disclosed |
| US-4342689-A | HYPOTENSIVE AGENTS | AMERICAN CYANAMID COMPANY (US) | 1982-08-03 | — | — | US | disclosed |
| US-4342691-A | HYPOTENSIVE AGENTS | AMERICAN CYANAMID COMPANY (US) | 1982-08-03 | — | — | US | disclosed |
| US-4299769-A | HYPOTENSIVE AGENTS | AMERICAN CYANAMID COMPANY (US) | 1981-11-10 | — | — | US | disclosed |
| US-4136184-A | TRANQUILIZERS, ANTICONVULSANTS, MUSCLE RELAXANTS | SANDOZ, INC. (US) | 1979-01-23 | — | — | US | disclosed |
| US-4055644-A | CNS DEPRESSANTS | SANDOZ, INC. (US) | 1977-10-25 | — | — | US | disclosed |
| US-3931176-A | CNS DEPRESSANT | SANDOZ INC. (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | SSU72, POLR2H, POLR2E | CTNNB1 4645/4885WNT3A 4748/4885LMNA 3432/4885 |
| US-11718588-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | ADAMTS1, ADAMTS5, ADAMTS7 | CTNNB1 1867/4885WNT3A 687/4885LMNA 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.